| 제2형 당뇨병 환자의 약제치료 개정안 2017: 경구혈당강하제 단일요법 |
|
이상열 |
|
|
| Monotherapy in Type 2 Diabetes Mellitus Patients 2017: A Position Statement of the Korean Diabetes Association. |
|
Sang Youl Rhee |
|
On Behalf of the Committee of Clinical Practice Guideline of the Korean Diabetes Association, Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea. rheesy@khu.ac.kr |
|
|
| Abstract |
|
When starting initial medication in people with type 2 diabetes mellitus (T2DM), the appropriate drug should be selected considering characteristics of the patient, efficacy, side effects, and cost. It is generally recommended to use metformin as the first-line treatment oral hypoglycemic agent in T2DM patients. Metformin is recommended as the first treatment because of its excellent glucose lowering effect, relatively mild side effects, long-term safety, low risk of hypoglycemia, and small weight gain. If it is difficult to use metformin as a first-line treatment, appropriate drugs can be selected based on the clinical situation. |
| Key Words:
Diabetes mellitus, type 2, Hypoglycemic agents, Metformin, Practice guideline |
|
PDF Links
Full text via DOI
Download Citation
